Digital Health

The Africa Innovation and Healthcare Fund 1 (AHF-1) is a venture capital and impact fund managed by AAIC Investment, a Japan-based investment manager dedicated to advancing healthcare and innovation across the African continent. Launched in 2017 as Japan's first fund with an exclusive focus on the African healthcare sector, AHF-1 represents a pioneering effort to channel institutional capital from Japanese financial institutions and corporations into high-growth, mission-driven businesses across Sub-Saharan Africa. AHF-1 targets early- to late-stage companies operating across the full spectrum of healthcare and adjacent verticals, including clinical care, medical services, digital health, health technology, pharmaceutical distribution, insurance, diagnostics, and health-enabling infrastructure such as fintech and mobility. The fund takes equity positions and provides hands-on operational and strategic support to portfolio companies through AAIC's deep local networks in Kenya, Nigeria, Egypt, Rwanda, and other key African markets. The investment thesis centers on the belief that healthcare companies in Africa can achieve strong financial returns while addressing acute social challenges in underserved markets. AHF-1 reached a final close at USD 47 million and deployed capital across more than 30 startups and established companies, establishing AAIC Investment as one of the leading Japan-Africa impact investors in the private markets space. The fund's success laid the foundation for the Africa Innovation and Healthcare Fund 2 (AHF-2), launched in 2022 with a USD 150 million target, continuing to scale the manager's pan-African healthcare investment franchise. AAIC Holdings Pte. Ltd., headquartered in Singapore, serves as the parent organization with regional operations across Africa and Asia.

The Africa Innovation and Healthcare Fund 2 (AHF-2), managed by AAIC Investment, is the second vintage of Japan's leading Africa-focused healthcare and innovation fund series. Launched in April 2022, AHF-2 builds on the model established by AHF-1 (2017, final close USD 47 million) and targets a broader mandate spanning healthcare technology, digital health, fintech, and mobility companies driving sustainable growth across the African continent. AHF-2 has a target size of USD 150 million and reached its first close at the end of March 2022, attracting Japanese institutional investors and corporations as limited partners. Key investors include the Development Bank of Japan (DBJ), QR Investment (Hokkoku Financial Holdings Group), TOPPAN Holdings, and Marubeni Corporation, reflecting strong interest from Japan's corporate sector in gaining strategic exposure to Africa's high-growth technology and healthcare ecosystem. By October 2023, the combined capital committed across AHF-1 and AHF-2 stood at USD 87 million (approximately JPY 13 billion), with the fund continuing to accept subscriptions toward its USD 150 million target. As of the second close in September 2023, AAIC Investment had deployed capital across 45 portfolio companies through both funds, spanning diagnostics, pharmaceuticals, insurance, digital health platforms, and health-enabling fintech across Kenya, Nigeria, Egypt, South Africa, and Rwanda. AAIC Investment, headquartered in Singapore through parent AAIC Holdings Pte. Ltd., brings over a decade of on-the-ground Africa experience combined with access to Japanese capital, technology, and corporate partnerships, positioning AHF-2 as a distinctive bridge fund between Japanese institutional capital and African innovation ecosystems.

The Africa Innovation and Healthcare Fund 2 (AHF-2), managed by AAIC Investment, is the second vintage of Japan's leading Africa-focused healthcare and innovation fund series. Launched in April 2022, AHF-2 builds on the model established by AHF-1 (2017, final close USD 47 million) and targets a broader mandate spanning healthcare technology, digital health, fintech, and mobility companies driving sustainable growth across the African continent. AHF-2 has a target size of USD 150 million and reached its first close at the end of March 2022, attracting Japanese institutional investors and corporations as limited partners. Key investors include the Development Bank of Japan (DBJ), QR Investment (Hokkoku Financial Holdings Group), TOPPAN Holdings, and Marubeni Corporation, reflecting strong interest from Japan's corporate sector in gaining strategic exposure to Africa's high-growth technology and healthcare ecosystem. By October 2023, the combined capital committed across AHF-1 and AHF-2 stood at USD 87 million (approximately JPY 13 billion), with the fund continuing to accept subscriptions toward its USD 150 million target. As of the second close in September 2023, AAIC Investment had deployed capital across 45 portfolio companies through both funds, spanning diagnostics, pharmaceuticals, insurance, digital health platforms, and health-enabling fintech across Kenya, Nigeria, Egypt, South Africa, and Rwanda. AAIC Investment, headquartered in Singapore through parent AAIC Holdings Pte. Ltd., brings over a decade of on-the-ground Africa experience combined with access to Japanese capital, technology, and corporate partnerships, positioning AHF-2 as a distinctive bridge fund between Japanese institutional capital and African innovation ecosystems.

The Africa Innovation and Healthcare Fund 2 (AHF-2), managed by AAIC Investment, is the second vintage of Japan's leading Africa-focused healthcare and innovation fund series. Launched in April 2022, AHF-2 builds on the model established by AHF-1 (2017, final close USD 47 million) and targets a broader mandate spanning healthcare technology, digital health, fintech, and mobility companies driving sustainable growth across the African continent. AHF-2 has a target size of USD 150 million and reached its first close at the end of March 2022, attracting Japanese institutional investors and corporations as limited partners. Key investors include the Development Bank of Japan (DBJ), QR Investment (Hokkoku Financial Holdings Group), TOPPAN Holdings, and Marubeni Corporation, reflecting strong interest from Japan's corporate sector in gaining strategic exposure to Africa's high-growth technology and healthcare ecosystem. By October 2023, the combined capital committed across AHF-1 and AHF-2 stood at USD 87 million (approximately JPY 13 billion), with the fund continuing to accept subscriptions toward its USD 150 million target. As of the second close in September 2023, AAIC Investment had deployed capital across 45 portfolio companies through both funds, spanning diagnostics, pharmaceuticals, insurance, digital health platforms, and health-enabling fintech across Kenya, Nigeria, Egypt, South Africa, and Rwanda. AAIC Investment, headquartered in Singapore through parent AAIC Holdings Pte. Ltd., brings over a decade of on-the-ground Africa experience combined with access to Japanese capital, technology, and corporate partnerships, positioning AHF-2 as a distinctive bridge fund between Japanese institutional capital and African innovation ecosystems.

The Africa Innovation and Healthcare Fund 2 (AHF-2), managed by AAIC Investment, is the second vintage of Japan's leading Africa-focused healthcare and innovation fund series. Launched in April 2022, AHF-2 builds on the model established by AHF-1 (2017, final close USD 47 million) and targets a broader mandate spanning healthcare technology, digital health, fintech, and mobility companies driving sustainable growth across the African continent. AHF-2 has a target size of USD 150 million and reached its first close at the end of March 2022, attracting Japanese institutional investors and corporations as limited partners. Key investors include the Development Bank of Japan (DBJ), QR Investment (Hokkoku Financial Holdings Group), TOPPAN Holdings, and Marubeni Corporation, reflecting strong interest from Japan's corporate sector in gaining strategic exposure to Africa's high-growth technology and healthcare ecosystem. By October 2023, the combined capital committed across AHF-1 and AHF-2 stood at USD 87 million (approximately JPY 13 billion), with the fund continuing to accept subscriptions toward its USD 150 million target. As of the second close in September 2023, AAIC Investment had deployed capital across 45 portfolio companies through both funds, spanning diagnostics, pharmaceuticals, insurance, digital health platforms, and health-enabling fintech across Kenya, Nigeria, Egypt, South Africa, and Rwanda. AAIC Investment, headquartered in Singapore through parent AAIC Holdings Pte. Ltd., brings over a decade of on-the-ground Africa experience combined with access to Japanese capital, technology, and corporate partnerships, positioning AHF-2 as a distinctive bridge fund between Japanese institutional capital and African innovation ecosystems.

Cathay InnoSquare is the fund-of-funds programme managed by Cathay Innovation, a Paris-based multi-stage venture capital firm founded in 2015 with more than €2.5 billion in assets under management across its fund family. The InnoSquare programme is dedicated to identifying and backing the next generation of early-stage venture capital managers across North America, Europe, and Asia, with a specific focus on emerging managers raising their Fund I through Fund III. The fund's strategy rests on the conviction that the most outsized returns in venture capital often originate from emerging managers with concentrated portfolios, differentiated deal-sourcing networks, and theses closely aligned with the digital revolution. Cathay InnoSquare targets fund managers investing at the seed and early stages in companies operating at the intersection of digital transformation, artificial intelligence, and healthcare technology. By backing managers early in their institutional lifecycle, the programme secures access to high-quality proprietary deal flow while supporting the development of a more globally diverse venture ecosystem. As part of Cathay Innovation's broader platform, Cathay InnoSquare portfolio managers gain access to the firm's global network spanning five continents, connecting major innovation hubs, institutional investors, corporate partners, and Fortune 500 companies across Paris, San Francisco, Shanghai, and Singapore. This value-add layer reflects Cathay Innovation's positioning as a cross-border bridge between European, North American, and Asian innovation ecosystems. Portfolio managers also benefit from Cathay's co-investment capabilities, leveraged through its flagship VC funds that invest directly in startups alongside portfolio managers. InnoSquare has participated in fundraises for several US-based climate and deep-tech venture funds, including as an LP in VoLo Earth's Fund II, a Colorado-based energy transition vehicle.

Columbus Innvierte Life Science I is the debut venture capital fund managed by Columbus Venture Partners, a Valencia, Spain-based life sciences investor founded in 2016 by Javier García and Damià Tormo. The fund was registered with the Spanish securities regulator CNMV (registration no. 190) and launched in April 2016 as part of Spain's Innvierte programme, a public-private co-investment initiative supporting early-stage innovation. The fund raised EUR 42 million and had an investment period running from 2016 to 2018, making seed and Series A investments in deep biotech and advanced therapy companies, primarily in Spain. The fund's strategy combined scientific expertise in therapeutic development with an industrial vision, targeting companies working on cell and gene therapies, AAV vector manufacturing, and other disruptive life sciences platforms. Columbus Venture Partners brought a distinctive approach of investing in both product development and the manufacturing infrastructure required to scale these technologies, thereby shortening time to exit. The geographic focus was Spain with international reach, co-investing alongside specialist international and corporate venture funds. The fund built a portfolio of eight investments and has since generated exceptional returns through landmark exits. Viralgen Vector Core was sold to Bayer in 2020 in a transaction valued at approximately EUR 4 billion. Vivet Therapeutics was acquired by Pfizer for an upfront and option value of EUR 560 million. Aura Biosciences completed a NASDAQ IPO in 2021. Columbus Venture Partners now manages over EUR 400 million across four successive funds, establishing itself as one of Spain's leading life sciences venture capital franchises.

Eoniq Mediterranean Seed Fund I FCRE S.A. is an early-stage venture capital fund registered with Spain's Comisión Nacional del Mercado de Valores (CNMV) and managed by Eoniq.fund, a Madrid and Seville-based venture capital manager. The fund targets pre-seed and seed-stage technology startups founded or led by Spanish entrepreneurs, with particular focus on founders operating outside the major hubs of Madrid and Barcelona, supporting emerging innovation ecosystems across Spain and the broader Mediterranean region. The FCRE S.A. legal structure is a Spanish closed-end venture capital vehicle authorized under European Alternative Investment Fund Manager regulations, providing institutional governance standards aligned with AIFMD requirements. Eoniq Mediterranean Seed Fund I pursues a generalist technology venture strategy at the earliest stages of company formation, investing in startups that demonstrate initial product-market fit through a minimum viable product and early traction metrics. The fund takes an active value-add approach, providing portfolio companies with access to the Eoniq network of experienced operators, domain advisors, and follow-on institutional investors to support internationalization and growth beyond the Iberian market. With approximately 50 portfolio companies invested from Fund I, the portfolio reflects a diversified early-stage approach spanning consumer technology, enterprise software, digital health, and marketplace business models. The Eoniq investment team brings a verifiable pre-fund track record of over 60 individual angel and pre-institutional investments prior to raising Fund I, with reported returns of 6.36x and an IRR exceeding 35%. This track record reflects demonstrated ability to identify and back exceptional founding teams at the earliest stages across Spain's emerging startup ecosystem. The CNMV registration and regulated fund structure attract co-investors and institutional limited partners seeking controlled-risk exposure to the Spanish and Mediterranean venture ecosystem through a supervised investment vehicle.

Foresite Capital Fund V, L.P. is a multi-stage healthcare and life sciences venture capital fund managed by Foresite Capital, a San Francisco-based investment firm founded in 2011 by Dr. Jim Tananbaum. Closing in February 2021 at $775 million — above its initial target — Fund V represents the fifth flagship vehicle in Foresite's franchise, which collectively manages approximately $4 billion in assets across the full continuum of healthcare innovation. The fund's strategy spans the entire development arc of healthcare companies, from early incubation and seed-stage biotech to late-stage clinical companies and public equity. Fund V focuses on precision medicine, therapeutics, genomics and life science infrastructure, including the data science and automation tools that underpin modern drug discovery. Foresite applies deep scientific diligence alongside capital markets expertise, given the firm's unique position investing through IPO and into the public markets — a hybrid approach that distinguishes it from purely private-market VC funds. Portfolio investments from Fund V include 10x Genomics, Element Biosciences, Relay Therapeutics, Lyell Immunopharma, and Inscripta. Foresite Capital Fund V was seeded by a diverse base of institutional investors including university endowments, public and private pension funds, insurance companies, foundations, corporate investors, and prominent family offices worldwide. By the date of the final close, the firm's track record encompassed more than 47 IPO events and 28 M&A exits. The fund is domiciled in Delaware and was registered with the SEC under CIK 1822711.

Foresite Capital Opportunity Fund V, L.P. is a dedicated follow-on investment vehicle managed by Foresite Capital, the San Francisco-based multi-stage healthcare venture capital firm. Closed concurrently with Foresite Capital Fund V in February 2021 at $193.75 million, the Opportunity Fund represents a targeted co-investment sleeve designed to make concentrated, higher-conviction incremental positions in the highest-quality companies in Fund V's portfolio as they approach IPO and beyond. The Opportunity Fund's strategy is complementary to the flagship Fund V: rather than building a new portfolio from scratch, it selectively adds capital to existing portfolio companies at critical inflection points — typically late-stage clinical milestones, pre-IPO financings, or crossover rounds — where Foresite's scientific and capital-markets diligence has already been performed. This structure allows LPs to concentrate exposure to Foresite's highest-conviction holdings while maintaining liquidity flexibility, a key advantage in the healthcare sector where development timelines and go-public windows can be uncertain. Target sectors mirror the flagship fund: precision medicine, therapeutics, genomics, digital health, and life science data infrastructure. Together, Foresite Capital Fund V and the Opportunity Fund V raised a combined $968.75 million (reported publicly as approximately $969 million), reflecting strong demand from a global LP base including public pension funds, university endowments, foundations, and family offices. The Arizona State Retirement System was among the LPs confirmed in public disclosures. The fund is structured as a Delaware limited partnership and registered with the SEC under CIK 1792205.

Inveready Innvierte Biotech II is a Spanish venture capital fund managed by Inveready, one of Spain's most active alternative investment firms managing over €2.2 billion in assets across venture capital and private equity strategies. Established in 2013 and structured as a Sociedad de Capital Riesgo (S.C.R.) under CNMV regulation, the fund was co-sponsored under the Spanish government's Innvierte program, which promoted private investment in innovative companies by matching institutional capital with public co-investment. The fund invested across a portfolio of 22 life sciences companies, with 94% of capital allocated to Spanish companies, making it one of the most concentrated dedicated biotech venture funds in Spain during its investment period.Inveready Innvierte Biotech II deployed capital at the early stages of the life sciences value chain, focusing on companies at the seed and Series A stage across drug development (47% of the portfolio), over-the-counter products, medical services, and digital health. The fund adopted a multi-stage strategy, following companies from initial investment through clinical development and commercialization. The fund management team was led by Sara Secall, Roger Piqué, and Josep Maria Echarri, who brought deep sector expertise in pharmaceutical sciences, biotech commercialization, and venture capital to the portfolio management process. The fund's geographic focus on Spain allowed it to build a concentrated exposure to the domestic biotech ecosystem at a formative period in its development.Inveready Innvierte Biotech II was fully divested, delivering a 4.3x return on invested capital to its shareholders — making it the fourth venture capital fund Inveready has successfully exited, all with markedly positive results. Notable exits include Avizorex, the first venture-backed Spanish company to complete the full drug development cycle and receive U.S. marketing authorization from Alcon (world leader in ophthalmology) for an ophthalmic drug; the sale of stakes in Reva Health and Zera; and the IPO and subsequent divestment of Edesa Biotech on Nasdaq and Atrys Health on the Spanish Mercado Continuo. Portfolio companies created over 2,500 direct jobs — 57% held by women — and attracted more than €500 million in follow-on investment, with over €200 million allocated to R&D activities.